Hannah Valantine Sells Shares of CDNA
Hannah Valantine sold 12,103 shares of CDNA in a planned transaction on June 15, 2026.
Key Points
- Hannah Valantine sold 12,103 shares of CDNA on June 15, 2026, in a planned sale, netting approximately $279,700.
- Shares of CDNA traded near $24.08 with analysts maintaining varied ratings and price targets.
- Institutional investors like BlackRock and BAMCO also adjusted their positions in CDNA recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Hannah Valantine sold 12,103 shares of CDNA in a planned transaction. The shares were sold at an average price of $23.11, bringing the total value of the sale to approximately $279,700. This sale was part of a pre-arranged trading plan.
Other Institutional Activity in CDNA
Several institutional investors also made moves in CDNA recently. BlackRock, Inc. reduced its holdings by 128,313 shares, ending with 4,522,096 shares valued at about $78.5 million. Meanwhile, BAMCO Inc. increased its position by 181,229 shares, holding 3,336,409 shares worth approximately $57.9 million. State Street Corp added 22,633 shares, bringing its total to 2,760,385 shares valued at $47.9 million. ARK Investment Management LLC increased its stake by 91,153 shares, now holding 2,227,556 shares valued at around $38.7 million. Braidwell LP made a notable increase of 587,926 shares, resulting in 2,173,146 shares worth about $37.7 million.
CareDx, Inc. Stock Down 51.6%
Shares of CDNA traded near $24.08. The stock has experienced a range over the past 52 weeks, with a low of $19.00 and a high of $28.50. Investors are watching how the stock performs amid these insider and institutional activities.
$CDNA stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at CareDx, Inc.
In addition to Hannah Valantine's planned sale, several insiders were involved in transactions around the same period. On June 12, 2026, Christine Cournoyer, Suresh Gunasekaran, Fred Cohen, and George Bickerstaff each purchased 9,795 shares. These transactions were not planned, contrasting with Valantine's planned sale.
Analysts Set New Price Targets
Analysts have been active in setting price targets for CDNA. On April 29, 2026, BTIG maintained its 'buy' rating with a price target of $28. Earlier in February, BTIG also maintained a 'buy' rating with a $26 target. Wells Fargo, on February 25, 2026, maintained a 'hold' rating with a $21 target. The consensus among analysts suggests a mixed outlook, with a range of price targets reflecting varying expectations.
Bottom Line
Hannah Valantine's recent planned sale of CDNA shares highlights ongoing insider activity, which investors often track for insights into company sentiment. Institutional investors have also adjusted their holdings, reflecting diverse strategies. While the stock's performance continues to be monitored, analysts' mixed ratings and targets suggest varied opinions on its future trajectory.
Get CareDx, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CDNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.